Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels

被引:28
作者
Kobayashi, I
Nogaki, F
Kusano, H
Ono, T
Miyawaki, S
Yoshida, H
Muso, E
机构
[1] Kitano Hosp, Tazuke Kofukai Med Res Inst, Div Nephrol & Dialysis, Kita Ku, Osaka 5308480, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan
[3] Nippon Shinyaku Co Ltd, Res Labs, Kyoto 601, Japan
[4] Fukui Med Univ, Dept Clin Lab Med & Nephrol, Fukui, Japan
关键词
anionic charge; crescent formation; glycoprotein; helper T cell; IgA nephropathy; polymeric IgA;
D O I
10.1093/ndt/17.12.2108
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. We recently developed a ddY mouse strain having high IgA levels (HIGA) that provided a murine model of IgA nephropathy. We additionally showed that administration of interleukin (IL)-12, a potent helper T (Th)1-inducing cytokine, induced an apparent reduction in serum IgA levels. In the present study, we assessed the influence of IL-12 administration on several physicochemical characteristics of nephritogenic IgA molecules in HIGA mice. Methods. HIGA mice received daily intraperitoneal injections of IL-12 or control injections of phosphate-buffered saline for 3 weeks. Crescent formation and levels of circulating and glomerular IgA were analysed. Moreover, potential changes in charge, size, and glycosylation of serum and glomerular IgA were investigated. Results. In the IL-12 group, glomerular IgA deposition was faint, although crescent formation was more marked than in the control group. Serum IgA levels in IL-12 mice were significantly lower than in controls. IL-12-treated mice also showed markedly decreased acidic and polymeric IgA both in sera and in glomerular eluate. A lectin-binding study revealed a markedly reduced ratio of sialylated and galactosylated IgA in the sera and in glomerular eluate from HIGA mice kidneys. IL-12 treatment significantly increased sialylation and galactosylation of circulating IgA, although glycosylation of IgA in glomerular eluate remained low. Conclusions. In HIGA mice showing under-glycosylation, IL-12 administration may lead to changes in the physicochemical characteristics of IgA, and this may occur through a shift to Th1. These results suggest that the Th1 and Th2 balance might play a role in the development of immunopathologic lesions in this model of IgA nephropathy.
引用
收藏
页码:2108 / 2116
页数:9
相关论文
共 17 条
[1]   Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients [J].
Allen, AC ;
Bailey, EM ;
Brenchley, PEC ;
Buck, KS ;
Barratt, J ;
Feehally, J .
KIDNEY INTERNATIONAL, 2001, 60 (03) :969-973
[2]  
Allen AC, 1999, J AM SOC NEPHROL, V10, P1763
[3]   Identification of a novel Fcα receptor expressed by human mesangial cells [J].
Barratt, J ;
Greer, MR ;
Pawluczyk, IZA ;
Allen, AC ;
Bailey, EM ;
Buck, KS ;
Feehally, J .
KIDNEY INTERNATIONAL, 2000, 57 (05) :1936-1948
[4]  
Chintalacharuvu SR, 1997, J IMMUNOL, V159, P2327
[5]   T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation [J].
Chintalacharuvu, SR ;
Nagy, NU ;
Sigmund, N ;
Nedrud, JG ;
Amm, MEL ;
Emancipator, SN .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 126 (02) :326-333
[6]   Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy [J].
Hiki, Y ;
Odani, H ;
Takahashi, M ;
Yasuda, Y ;
Nishimoto, A ;
Iwase, H ;
Shinzato, T ;
Kobayashi, Y ;
Maeda, K .
KIDNEY INTERNATIONAL, 2001, 59 (03) :1077-1085
[7]  
Ichinose H, 1996, CLIN EXP IMMUNOL, V103, P125
[8]   Interleukin-4 and interleukin-l0 attenuate established crescentic glomerulonephritis in mice [J].
Kitching, AR ;
Tipping, PG ;
Huang, XR ;
Mutch, DA ;
Holdsworth, SR .
KIDNEY INTERNATIONAL, 1997, 52 (01) :52-59
[9]  
Kokubo T, 1998, J AM SOC NEPHROL, V9, P2048
[10]   Increased sialylation of polymeric λ-IgA1 in patients with IgA nephropathy [J].
Leung, JCK ;
Tang, SCW ;
Chan, DTM ;
Lui, SL ;
Lai, KN .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2002, 16 (01) :11-19